Genetic Testing and Personalized Treatment for Kidney Stone Formers

Review finds genetic testing pays off in high-risk cases, but polygenic risk scores remain unproven for most patients

Journal: Current Opinion in Urology | Published: 2026-03-12 | Type: Review | PMID: 41830054 Authors: Robert Geraghty (Newcastle upon Tyne NHS Foundation Trust), Sarah Howles (University of Oxford, Nuffield Department of Surgical Sciences), John Sayer (Newcastle University, Biosciences Institute) Funding/COI: Not disclosed

Summary

Kidney stone disease is partly heritable, and genetic testing can identify monogenic causes in highly selected patients — those with strong family history and recurrent stones. In those narrowly defined cohorts, diagnostic yields are high enough to change clinical management. For the broader, unselected population walking into a urology clinic, the evidence for genetic screening, including polygenic risk scores, is thin and the criteria for patient selection remain undefined.

Claims

• Genetic testing for monogenic kidney stone disease yields high diagnostic rates in "highly selected cohorts" — no aggregate diagnostic yield figure provided
• Confirmed monogenic diagnoses enable genetic counselling, cascade family testing, and targeted therapies
• The role of rare intermediate-effect and common low-effect genetic variants is described as "evolving" — no quantified contribution reported
• Clinical utility of polygenic risk scores in unselected cohorts is explicitly called "uncertain"
• Current guidance supports testing for individuals with recurrent stones and strong family history
• Authors identify a gap: no large-scale studies in real-world urology settings exist to define optimal selection criteria

Study Quality

This is a narrative review, not a systematic review or meta-analysis. No search strategy is reported, no inclusion/exclusion criteria, no pooled estimates. The authors summarize the existing evidence landscape and highlight gaps, which is appropriate for the journal format (Current Opinion in Urology publishes opinion-and-overview pieces by design), but the conclusions carry the evidentiary weight of expert opinion, not data synthesis.

The absence of funding and COI disclosures is a meaningful gap. All three authors are affiliated with UK academic urology and genetics programs — Newcastle and Oxford are both active in monogenic kidney stone research — which may shape which findings receive emphasis.

Red Flags

• Narrative review: no systematic search, no PRISMA, no pooled data — susceptible to selection bias in which studies are cited
• "Highly selected cohorts" do the heavy lifting throughout; generalizability to routine urology practice is not established
• No specific diagnostic yield numbers are reported despite this being the key clinical question
• Funding and conflicts of interest not disclosed; two of three institutions are research-active in this specific area
• "Evolving understanding" and "further research required" appear repeatedly — this paper describes a field, not a finding
• Polygenic risk score utility is flagged as uncertain but the review does not quantify the degree of uncertainty or summarize negative evidence

Strengths

• Correctly scoped: distinguishes monogenic disease (rare, high penetrance, clinically actionable) from polygenic risk (common, low effect, uncertain utility)
• Practically useful framing: family history plus recurrent stones as the selection trigger is a concrete clinical signal
• Identifies the right evidence gap — lack of large urology-based cohort studies — and doesn't oversell what exists
• Oxford and Newcastle groups have direct experience with monogenic KSD, lending the authors credibility in their domain

Verdict

This review accurately maps where genetic testing for kidney stones stands: useful in a narrow, well-defined high-risk group; unproven everywhere else. It does not pretend otherwise. The problem is it offers no new data — it is a summary of a summary, without the methodological rigor of a systematic review. If you work in a urology clinic trying to decide who to send for genetic testing, the "recurrent stones plus family history" signal is a reasonable takeaway, but this paper won't tell you what yield to expect or what the testing should actually include. For researchers, the gap it identifies — large-scale, real-world urology cohort studies — is real and worth noting.